HSP90B2P and non-small cell lung carcinoma: A phase Ib/II clinical study in non-small cell lung cancer (NSCLC) evaluated the combination of anti-PD1 (nivolumab) with an allogeneic lung tumor cell vaccine secreting Gp96-Ig HSP-peptide complexes and Fc-OX40L costimulatory molecules (Viagenpumatucel-L).